Index

Page numbers in italics refer to figures.

abortion, 51, 130, 134, 144n20
adoption, 79, 81, 92, 96, 106, 110–11, 147n3
adulteration, 105
Agarwal family, 44, 46, 50–51
ampoules, 24, 30–31, 34. See also hCG; Pregnyl
Anand Kumar, T. C., 46–47, 49, 51, 55, 58, 63, 145n8
anxieties: about mix-ups and boundary crossings, 20, 101–4, 112–13, 116–17; about possible abnormalities, 44–45, 51; prevalence of, 139
archival research, 15
Aspen Pharma, 143n8
assisted reproductive technologies, 1–6. See also global reproductive medicine; ICSI; infertility management; IUI; IVF
Bengal Obstetrics and Gynaecological Society, 45, 53
Bhattacharya, Saroj Kanti, 42
Bhore Committee, 66, 145n5(chap.3)
bioeconomies, 8, 12, 24
biological substances, 1, 5–10; relational constitution of, 9–10, 139; relational potential, 7–9, 103–5; transnational flows of, 6–7, 18–19, 22–37, 137, 141n12. See also bodies; egg cells; embryos; gametes; hCG; reproductive substances; semen; sperm; urine
biosociality, 115
birth control, 11
bodies: chronological and gynecological age of, 83; corporeal generosity, 29–31; mal-leableness and resistance, 100; productivity, 29–31, 85–86, 100, 147n10; relations and, 9–10; response of, 85–87; somatic activity, 100; somatic rhythms, 84–88, 100; unpredictability of, 86, 100. See also biological substances
Bose, Satyendra Nath, 53
boundary transgressions, 20, 101–4, 112–13, 115–17
Bourn Hall Clinic, UK, 13, 63
bricolage, 56
Brown, Louise, 42, 46, 63
capitalism, 20, 24, 116, 138
caste, 7–8, 20, 28, 101–4, 110–11, 115–17
Catholic Church, 129, 143n7
Chakraborty, Baidyanath, 1–3, 53–55, 60–61, 145n1
charitable hospitals, 65–66, 69, 71, 74. See also hospitals
Chhetri, Mani, 43
cildbearing, 79, 106, 134, 147n11, 148n4(chap. 5).
See also IVF babies
classed relations, 24; donor gametes and, 108, 115–16; IVF research and, 149n12; urine collection programs and, 28, 34–36. See also middle-class patients; working-class patients
clinical practice, 20, 76–100, 139–40; bodily rhythms and, 84–88, 100; division of medical labor, 67; improvised interventions, 60–64, 74; mundane, 78, 139; objects of, 20 (see also bodies; embryos; gametes). See also doctors; embryologists; IVF colonialism, 8–9, 13, 36, 54
commercial donors, 107–9, 116–17, 148n7. See also donor gametes
conception, natural, 96–97, 147n15
contraceptive pill, 26, 33, 84, 144n13
corporate hospitals, 60, 69–71, 75, 146n7(chap. 3). See also hospitals
corporeal matter, 6–7, 141n12. See also biological substances; bodies
costs: of corporate hospitals, 146n7(chap. 3); high-cost hospitals, 9, 72, 75, 115, 140; of
costs (continued)
IVF cycles, 14, 64, 73, 75, 80–81, 93, 115, 146n9; low-cost hospitals, 9, 73, 75, 103, 111–15, 140
cryopreservation, 51, 53–54, 56, 114, 120, 130–31, 134
culture media, 64–65, 124–25, 148n4–5(chap. 6)

Delhi, IVF hospitals and clinics in, 15–16, 65–73. See also hospitals
destiny (kismat), 90–92, 147n13
diffusion, 41–42, 137
disappointment, 88–92, 97, 99
doctors, 1–3, 16–19; IVF research by, 52–53, 58–64; pharmaceutical companies and, 32; trust in, 112–13, 117. See also hospitals; laboratories
donor gametes, 8, 95, 147n3; boundary transgressions and, 101–3, 115–18; egg sharing, 115–16; mismatches and, 105–12; ownership over, 115, 118; physical appearance and hereditary characteristics, 109–10; rumors of redistribution, 113–15. See also commercial donors; egg donation; known donors; sperm donation
Dr. Subhas Mukherjee Memorial Reproductive Biology Research Centre (Memorial Centre), 46–47, 48, 55
drugs. See fertility drugs
Durga (Kanupriya Agarwal), 45–46, 54
economic productivity, 12–14, 31–33, 138. See also political economy
economic reforms, 13, 35–36, 64, 66, 142n14
Edwards, Robert G., 40, 46, 63, 145n10
egg cells: relational potential of, 76; rumors of redistribution, 113–15; sharing of, 115–16; social identity and, 106. See also biological substances; gametes; reproductive substances
egg donation, 8, 106–8
embryo donation, 147n3
embryologists, 20–21, 119–35; educational qualifications, 67, 121–22; ethics and, 121–22, 129–35, 149n6; freelance, 84, 121–22, 147n8; IVF research, 62, 64; laboratory conditions and, 112–13. See also hospitals; laboratories
embryos: culture of, 122–25; disposal of, 129–34; enhancement of, 125–26, 148n9; form of existence, 129–31; process of becoming, 131–35; relations and, 9–10, 20–21; selection of, 127–29, 133; transfer of, 54, 87, 126, 147n9; unpredictability of, 20–21, 119–21, 126, 129, 134–35; use of term, 148n1. See also biological substances; reproductive substances
EmbryoScope, 127–28
epistemic exclusion, 37, 40–42
ethnographic method, 3, 5–6, 14–18, 113, 141n13, 142n19
experimentality, 60–64, 145n2. See also IVF research
extractive mechanisms, 24, 36
fallopian tubes, blocked, 44–46, 82–83, 90, 97, 147n15
family planning, 11, 33, 55, 58, 138, 144n19
fertility drugs: costs of, 73, 93, 115; produced in India, 136; side effects of, 97–99; transnational flows of, 136; used in ovarian stimulation, 85–86. See also gonadotropins; hCG; hMG
fertilization, 59, 61, 87, 112, 126–27, 130–31, 141n8
fetal reductions, 134
financial investments, 137; transnational flows of, 4, 6, 60, 69. See also corporate hospitals; private IVF clinics
Foreign Exchange Regulation Act (1973), 27, 143n12
gametes: ownership over, 9, 111, 115; relational potential of, 9–10, 76–78, 106–9. See also biological substances; donor gametes; egg cells; reproductive substances; semen; sperm
G-Club, 25, 42
gendered relations, 24, 36, 106, 146n3, 148n4(chap. 5)
genetic screening, 149n10
Ghosh Dastidar, Sudarsan, 60, 63
global North, 4, 22; bioeconomies of, 8–9, 36; knowledge production and, 41–42
global reproductive medicine: as an assemblage, 5–6, 10, 139–40; India’s role in formation of, 1–6, 10–14, 60, 136–40; spatial scales, 5–6; temporal scales, 4–6. See also infertility management; IVF
INDEX

global South: colonial extraction and, 8–9, 13, 36; epistemic exclusion and, 40–42, 54; fertility of urban poor in, 22, 36 (see also urine collection programs); infertility in, 12, 138; innovation and, 53; use of term, 141n6
god (ūparvālā or bhagvān), 89, 91–92, 132
gonadotropins, 25, 35, 143n3, 149n9. See also fertility drugs; hCG; hMG
gynecologists. See doctors
hCG (human chorionic gonadotropin): commodity chain, transnational, 7–8, 22–37, 136–37, 144n21, 149n1; global inequalities and, 35–36; industrial production of, 24–26; processes of valuation, 23–24; recombinant hCG, 23, 36, 73; urinary hCG, 23, 36, 73; uses of, 23–24, 31, 35. See also fertility drugs; gonadotropins; urine collection programs
health care policies, 27, 32, 60, 66, 71–72, 145n5(chap. 3)
hereditary transmission, 109–10
Hinduja, Indira, 58–64
hMG (human menopausal gonadotropin), 25, 143nn6–7. See also fertility drugs; gonadotropins; urine collection programs
Horlick powder, 29
hormones, 7–9, 142n2; alchemy of, 23–24; relations and, 9–10; research on, 25–26. See also fertility drugs; gonadotropins; hCG; hMG; ovarian stimulation
hospitals: boundaries between private and public institutions, 73–74; diversification of, 65–75; financial investments in, 69; high-cost, 9, 72, 75, 115, 140; low-cost, 9, 73, 75, 103, 111–15, 140. See also charitable hospitals; corporate hospitals; nursing homes; private IVF clinics; public hospitals
hypergamy, 105
hysteroscopy, 16, 142n17
ICSI (intracytoplasmic sperm injection), 16, 95, 126, 141n8, 142n17, 149n8
implantation, 87, 90, 126, 128, 130, 133
import duties, 7, 64–65
impurity: caste and, 104; in pharmaceutical production, 34–35; in scientific research spaces, 50
incestuous relations, 101, 103, 109, 116–17
incubators, 54, 64, 124, 128–29
India: globalized modernity, 11, 138; historical, political, and economic culture, 10–14, 55–56; national improvement, 110–12; relations between Netherlands and, 25, 27. See also economic reforms; global reproductive medicine; health care policies; legislation and regulations; population control programs
Indian Council of Medical Research, 12, 14, 46, 58, 61, 116, 145n1
Indian Medical Association, 45, 52
Indian National Congress, 11
Indian Science Congress, 56
Indian Society for Assisted Reproduction, 12
industrial production, 8–9, 22, 24–27, 32, 35–36
Infar, 143n12
infertility: diagnosis of, 81–83, 146n5(chap. 4); medicalization of, 79, 86; as moral condition, 79; rates of, 138; reproductive health programs and, 11, 71; as stagnation, 78–81; as unproductive state, 86
infertility management: hCG and, 34–36; regulation of, 14; technologization of, 11; timing of, 81–84, 146n4; unequal access to, 60. See also IVF cycles
infertility patients, 1–3, 12, 17–18, 20; admission process, 72–73; age of, 83; expenses (see costs); experiences of IVF cycles, 87–92; fears of (see anxieties); international, 62, 70; motivations for IVF treatment, 76–81; recruitment of, 71; religion and, 17, 107; treatment trajectories, 78, 83–100
infrastructure: lack of material, 53–56, 61; medical and financial, 13, 64–65, 74; technoscientific, 23, 26
innovation, 19, 40, 49–56. See also IVF research
Institute of Research in Reproduction, 11, 47, 58, 61, 63
insurance, 14, 73
International Federation of Fertility Societies, 12, 136, 137
in vivo simulation, 112, 123–25
IUI (intrauterine insemination), 83, 98, 142n17, 146n6(chap. 4), 148n3(chap. 6)
IVF (in vitro fertilization): commercialization of, 60, 63–64, 74; defined, 7; inequalities and, 9, 36, 118, 138; liminality of, 96–99; low-cost, 73, 75, 140; origin of (see IVF research); regulation and oversight, 14, 70, 117, 122, 139–40; routinization of, 55, 60, 64, 74, 139; technology of discontent, 139; terminology, 142n22. See also doctors; embryologists; global reproductive medicine; IVF cycles
IVF babies, 1–3; deliveries, 147n11; first recognized (in UK), 40–42, 46, 52, 145n7, 145n10; India’s first, 1, 36–38, 42, 44–46; India’s first scientifically documented, 58, 60, 62. See also Brown, Louise; Durga (Kanupriya Agarwal)

IVF centers. See hospitals

IVF cycles: costs of, 14, 64, 73, 75, 80–81, 93, 115, 146n9; failures and setbacks, 2, 10, 20, 88–92, 96–99, 132, 139, 147n14; health complications from, 97–99; hope and, 93–95; numbers of, 12; stages of, 87; temporal rhythms of, 20, 78, 84–88, 100; third-party, 104–12; uncertainty of, 2, 94–95, 129. See also donor gametes; infertility patients

IVF research, 11, 19, 38–75; as an innovation out of place, 49–55; on embryos, 149n12; facilities and supplies, 7, 49–50, 53–55; “garage inventions,” 56; as improvised interventions, 60–64; proof of success, 44–46; skills and expertise in, 54. See also IVF babies; knowledge claims; laboratories; scientific research; United Kingdom

Jones Institute, 61
jugār (bricolage), 56

karma, 90–91, 147n13

King Edward Memorial (KEM) Hospital, 58, 62–64

kinship, 7–8, 20, 104; gamete donation and, 106–9; new kinship studies, 104. See also donor gametes; relatedness

knowledge claims, 38–57; biomedical evidence, 44–47; contested, 42–44; epistemic exclusion and, 37, 40–42; innovation out of place, 49–55; recognition of, 40, 46–49, 55–57, 145n11; transnational flows of, 4, 6, 41–42, 137. See also IVF research; scientific research

knowledge production, 40; diffusion and, 41–42, 137; simultaneity of, 41, 57

known donors, 106–9. See also donor gametes

Kolkata: IVF research in, 136 (see also Chakraborty, Baidyanath; Ghosh Das-tidar, Sudarsan; Mukherjee, Subhas; Mukherjee, Sunit); urine collection programs in, 7–9, 22–37

laboratories, 119–35; andrology, 148n2; ethics and, 121–22, 129–34; location in clinics, 148n3; protocols, 112–13; scientific research in, 49–50, 55. See also embryologists; IVF research; scientific research

laparoscopy, 16, 142n15, 142n17

Laqueur, Ernst, 26

legislation and regulations, 14, 46–47, 56, 108–9, 111, 113, 115–16, 122, 139–40, 148n11, 148n13

life: life as such, 10; life ethics, 129–31, 134–35; life itself, 10; lifelessness, 86; pro-life debates, 10, 129

lineage, 79, 105. See also patrilineage

LIT (lymphocyte immunization therapy), 93–95

loan, 14, 80, 93

Lorraine, John A., 42

Lunenfeld, Bruno, 22, 25, 143n5, 144n17

Mahalanobis, Prasanta Chandra, 53

Martin & Harris (company), 27

media. See culture media

medical market, 4, 13, 26–27, 56, 60, 64–65, 70, 74, 117

medical supplies: access to, 32, 74; transnational flows of, 4, 6, 18–19, 60, 64–65, 137. See also fertility drugs; hCG; infrastructure

Medical Termination of Pregnancy Act (1971), 144n20

menstrual cycles, 84

middle-class patients: donor gametes and, 103, 115, 118; integrative socialities and, 110–12; upper-middle-class, 64, 67, 70

Ministry of Health and Family Welfare, 14

miscarriage, 134

mismatches, 105–12

mix-ups: accidental, 20, 103, 112–13; age of, 116–17; anxieties about, 8, 20

Moeders voor Moeders (Mothers for Mothers), 26, 31, 35, 143n8, 143n13

moral panics, 101, 103, 105, 116–18

morphological criteria, 127–28, 133

motherhood, 31, 35. See also parenthood “mothers for mothers” slogan, 30–31

Mukherjee, Subhas, 1, 4, 19, 33, 38–58, 39, 60–62, 136, 145n11, 145nn8–9

Mukherjee, Sunit, 38, 42, 44–45, 47, 48, 50–54, 56, 145n9

multinational companies (MNCs), 27, 143n12; legal restrictions on, 35–36. See also pharmaceutical companies

Mumbai, 11, 16, 35, 47; first publicly-funded IVF program, 58–64. See also Anand Kumar, T. C.; Hinduja, Indira; Institute of Research in Reproduction; King Edward Memorial (KEM) Hospital; National Institute for Research in Reproductive Health
National Guidelines for Accreditation, Supervision and Regulation of ART Clinics, 14, 46–47, 109, 113, 115, 122, 148n13
National Health Policy (1982), 66
National Institute for Research in Reproductive Health, 58, 59
National Planning Committee, 11
National Registry of Assisted Reproductive Technology (ART) Clinics and Banks, 12
Netherlands: pharmaceutical processing of hCG, 8–9, 22, 34–35; relations between India and, 25, 27; urine collection programs in, 26, 31, 35, 143n8, 143n13. See also Moeders voor Moeders; Organon
New Drug Policy (1978), 27
Nobel Prize in Physiology or Medicine, 40
nursing homes (entrepreneurial hospitals), 61, 65–71, 74, 146n8. See also hospitals
offspring, 2, 8, 76, 79, 81, 103, 109
OHSS (ovarian hyperstimulation syndrome), 98, 147n16
oocytes. See egg cells
Organon, 25–36, 143n8, 143nn11–13, 144n16, 144n21
ovarian stimulation, 56, 73, 84–88, 95, 100, 115
ovulation induction, 16, 142n17
Pacelli, Giulio, 25
parenthood: importance of, 78–81, 146n2; social pressure for, 82
Pasteur, Louis, 50
Patents Act (1970), 27
patients. See infertility patients
patrilineage, 8, 78–79, 103, 105–6
PCOS (polycystic ovarian syndrome), 93, 98
personhood, 7–8, 129–32
petri dishes, 87, 119, 124, 126, 133, 141n8
pharmaceutical companies, 25–36, 136. See also Infar; Organon; Serono
pharmaceuticals. See fertility drugs; hCG; hMG
Pius XII, Pope, 25
political economy, 8, 13, 24, 33, 142n14. See also economic productivity
population control programs, 11, 33–34, 36, 138
postmenopausal patients, 79
pregnancy, 79, 88; corporeal generosity and, 29–31; medical termination of, 134; precious, 147n11; substantial transactions during, 106; urine collection programs and, 23–24, 27–31. See also success rates
pregnancy tests, 33–34, 87, 134
Pregnyl (ampoule), 30–31, 34
private IVF clinics, 16–18, 58–71, 73–75, 146n8. See also hospitals
privatization of health care, 60, 66, 117
protectionism (government policies), 19, 24, 33
public hospitals, 12, 14, 16–18, 58–64, 71–74. See also hospitals
Purdy, Jean, 145n7
racialized relations, 24; donor gametes and, 109, 148n9; urine collection programs and, 28, 36
raw materials, 24–28, 31, 36–37, 137, 149n1. See also urine collection programs
regulations. See legislation and regulations
relatedness, 8, 103–4, 117. See also kinship relations: between academy and industry, 24–26; between centers and peripher­ies, 3–4, 41, 53–55; between Europe and India, 27; hCG and, 24–31; hidden, 3, 105, 107–9; inequality in, 3, 8–9, 118; between pregnant and infertile women, 23–24, 27–31; substances and, 6–10, 101–18; transnational, 3, 6–7, 60. See also classed relations; gendered relations; genealogical relations; incestuous relations; racialized relations; substantial relations
religion, 20, 101–3, 107, 110, 117; Christianity and embryo disposal, 129–31; Christian IVF patients, 107; Hindu IVF patients, 17, 62, 107; Muslim IVF patients, 17, 107
reproductive health, 11, 58, 71. See also global reproductive medicine; infertility management; IVF
reproductive substances, 6–7, 20–21, 76, 141n11. See also biological substances; egg cells; embryos; gametes; semen; sperm
responsibility: for biological substances, 135, 139; for infertility, 79–80, 90–92, 147n13; for parenthood, 45, 79
responsiveness, 100, 135, 139
rumors, 113–18
Saha, Meghnad, 53
scientific research: centers and peripheries, 3–4, 41, 53–55; conventions of, 51–53; in India, 32; industrial production and, 25–26; institutional structures and, 50–51, 56. See also IVF research; laboratories
secrecy and silence, 8, 103, 107–9, 118
self-sufficiency (government policies), 19, 24, 33
semen, 148n5 (chap. 6); analysis of, 79–80, 148n2. See also biological substances; gametes; reproductive substances; sperm
Serono, 25
silence. See secrecy and silence
Singh, Manmohan, 56
skin color, 109–10, 148n9
social inequalities, 8–9, 35–36, 118, 138, 140
social pressure, 82, 98
space: credibility of knowledge claims and, 49–55; modernist understanding of, 42; relational conceptualization of, 40, 42, 49
sperm: relational potential of, 76–78; social identity and, 106. See also biological substances; gametes; reproductive substances; semen
sperm donation: boundary transgressions and, 101–3; family members as donors, 106–9; mismatches and, 105–6. See also donor gametes
spirits (of deceased persons), 149n13
Steptoe, Patrick, 46
sterilization, 11
stratification: circulation of gametes and, 9, 111, 115–18; in society, 103–5; topologies, 7, 41; in treatment options, 60, 65, 73–74
structural adjustment programs, 66
substance-code, 7, 103–4, 141n12
substances, 2–3; constituted relationally, 9–10, 20–21, 139; relational potential of, 7–9, 20, 103–5; transnational flows of, 6–7, 18–19. See also biological substances; reproductive substances
substantial relations, 139; across social boundaries, 116–18; nonnormative, 101–18; quest for, 20, 78–81, 92, 96, 99. See also relations; substances
success rates, 64, 76, 94, 99, 119, 122, 146n1
surrogacy, 9, 14, 16, 95, 139
Surrogacy (Regulation) Bill, 14, 139
temporality, 4–6, 100; infertility defined by, 81–82; infertility management and, 81–84, 146n4; IVF cycles and, 20, 78, 84–88, 100
Test Tube Baby Get-Together, 1–3
trade regulations, 7, 64–65
ultrasound, 85, 134, 147n9
United Kingdom: IVF experiments, 40–42, 46, 52, 145n7, 145n10; IVF hospitals, 13, 63; regulation of IVF, 122. See also colonialism
United Nations International Conference on Population and Development, 11, 71
United States: entrepreneurial world in, 56; IVF regulations, 62; pro-life debates, 10
unknown donors. See commercial donors
unpredictability, 20–21, 100, 119–21, 126, 129, 134–35, 139
urine: relations and, 9–10; as substance, 30–31, 142n1, 144nn14–17
urine collection programs: in Kolkata, 7–9, 22–37; in the Netherlands, 26, 31, 35, 143n8, 143n13. See also fertility drugs; gonadotropins; hCG; hMG
valuation, processes of: embryo disposal, 129–34; embryo selection, 126–29; hCG and, 23–24, 35
van Oss, Jacques, 26
van Zwanenberg, Saal, 26
vital flows, 6–7
Waldby, Catherine, 76
West Bengal: Department of Health and Family Welfare, 43; industrial decline in, 35–36; Left Front government, 49; pharmaceutical sector, 31–33
working-class patients: donor gametes and, 115–16, 118; gamete circulations and, 103
World Health Organization (WHO), 61, 81–82, 138